Amgen
AMGN
$328.26
-0.26%
Amgen Inc. is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering innovative human therapeutics, operating within the Drug Manufacturers - General industry. The company is a dominant player with a diversified portfolio of flagship products across oncology, inflammation, bone health, cardiovascular, and rare diseases, solidified through strategic acquisitions like Horizon Therapeutics. The current investor narrative is dominated by the integration and performance of the Horizon acquisition, regulatory scrutiny over specific drugs like Tavneos, and navigating the evolving U.S. drug pricing and tariff landscape, which collectively drive debates about future growth sustainability and risk profile.…
AMGN
Amgen
$328.26
Related headlines
Investment Opinion: Should I buy AMGN Today?
Rating: Hold. The core thesis is that Amgen's attractive forward valuation and robust cash flows are currently offset by elevated balance sheet risk and near-term integration/regulatory uncertainties, warranting a neutral stance pending clearer execution evidence.
Supporting evidence for this Hold rating includes: 1) A compelling forward P/E of 14.35x, which prices in significant earnings growth, 2) Exceptional gross margin of 81.91% in the latest quarter, providing a wide moat, 3) Strong TTM free cash flow of $8.1 billion supporting the dividend and debt service, and 4) An analyst consensus that implies potential upside, with an average EPS estimate of $27.52. However, these positives are counterbalanced by a debt-to-equity ratio of 6.31 and recent quarterly earnings volatility.
The two biggest risks that could invalidate this thesis are a material deterioration in Tavneos' commercial prospects due to regulatory action, and a failure to achieve the projected earnings growth implied by the forward P/E, leading to multiple expansion. This Hold would upgrade to a Buy if the forward P/E compresses further toward 12x on sustained earnings delivery and debt reduction, or if the stock breaks below $300 offering a larger margin of safety. It would downgrade to a Sell if quarterly revenue growth decelerates below 5% YoY or if net income margins consistently fall below 15%. Relative to its own history and the implied growth, the stock appears fairly valued at current levels, neither egregiously overvalued nor deeply undervalued.
Sign up to view all
AMGN 12-Month Price Forecast
Amgen presents a classic 'show me' story. The valuation is undemanding if the company delivers on the promised Horizon earnings accretion, but the path is fraught with execution and regulatory risk. The high leverage amplifies both the potential upside and downside. The neutral stance reflects this balance, with a 55% probability assigned to the base case of adequate execution. Confidence is medium due to the quarterly volatility and external policy uncertainties. The stance would upgrade to bullish on evidence of consistent margin expansion and debt reduction, or downgrade to bearish on any confirmation that Tavneos' commercial potential is permanently impaired.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Amgen's 12-month outlook, with a consensus price target around $426.74 and implied upside of +30.0% versus the current price.
Average Target
$426.74
13 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
13
covering this stock
Price Range
$263 - $427
Analyst target range
Analyst coverage is moderate with 13 analysts providing estimates, indicating sustained institutional interest in this large-cap biotech. The consensus sentiment leans bullish to neutral, as evidenced by recent institutional actions including 'Buy' ratings from UBS and Argus Research and 'Outperform' from Leerink Partners, alongside several 'Neutral' or 'Equal Weight' stances from firms like Morgan Stanley and Citigroup. The average revenue estimate for the upcoming period is $42.69 billion, with a range from $41.56 billion to $44.28 billion, and the average EPS estimate is $27.52, ranging from $26.57 to $28.85; this relatively tight range on EPS suggests stronger conviction on near-term profitability, while the revenue range indicates some uncertainty around top-line growth, likely tied to the integration of new assets and pipeline execution.
Bulls vs Bears: AMGN Investment Factors
The investment debate for Amgen centers on a tension between its strong fundamental profitability and cash generation versus the substantial risks embedded in its leveraged balance sheet and regulatory environment. Currently, the bear case has stronger near-term evidence, driven by the stock's sharp 3-month underperformance, high debt burden (D/E of 6.31), and emerging Tavneos safety concerns. However, the bull case is supported by a compelling forward earnings valuation (14.35x P/E) and exceptional gross margins (81.91%). The single most important factor that will resolve the thesis is the successful integration and unencumbered commercial performance of the Horizon Therapeutics acquisition, which must justify the high leverage without further regulatory setbacks. If execution falters, the debt load becomes a critical vulnerability; if successful, the forward P/E suggests significant upside.
Bullish
- Strong Forward P/E Discount: The forward P/E of 14.35x is a significant discount to the trailing P/E of 22.84x, implying the market expects a substantial 37% increase in earnings. This expectation is anchored in the full integration of the Horizon acquisition and the realization of cost synergies, which could drive EPS toward the analyst average estimate of $27.52.
- Exceptional Gross Profitability: Amgen maintains industry-leading gross margins, with Q4 2025 reaching 81.91%. This high-margin profile provides significant financial flexibility to fund R&D, service debt, and return capital to shareholders, underpinning the company's durable cash generation as evidenced by $8.1 billion in TTM free cash flow.
- The company generates substantial free cash flow ($8.1 billion TTM), supporting its dividend (2.9% yield) and providing a buffer for its high debt load. This strong cash generation is a key pillar of financial stability and allows for continued strategic investments.
- Low Market Volatility (Beta): With a beta of 0.435, AMGN is significantly less volatile than the broader market. This characteristic makes it a defensive holding within healthcare, offering relative stability and lower portfolio risk, which is attractive in uncertain macroeconomic environments.
Bearish
- Extremely High Debt Burden: The debt-to-equity ratio of 6.31 is exceptionally high, reflecting the aggressive leverage used to fund the Horizon acquisition. This elevates financial risk, increases interest expense ($653M in Q4 2025), and limits strategic flexibility, making the company sensitive to rising rates.
- Significant Regulatory & Safety Risks: Recent news highlights severe regulatory scrutiny over Tavneos, including an FDA warning on fatal liver risks. This introduces material commercial, reputational, and financial risk for a key rare-disease asset acquired via Horizon, potentially jeopardizing expected revenue streams.
- Lumpy & Volatile Quarterly Performance: Revenue and net income show high quarterly volatility (e.g., net income swung from $3.22B in Q3 2025 to $1.33B in Q4 2025). This inconsistency, driven by acquisition integration and one-time items, complicates forecasting and undermines investor confidence in near-term stability.
- Sharp Recent Underperformance: The stock has significantly underperformed the market, down 13.23% over 3 months with a relative strength of -23.51 against the SPY. This technical breakdown from recent highs near $391 suggests negative momentum and a loss of investor favor despite the longer-term uptrend.
AMGN Technical Analysis
The stock is in a sustained uptrend over the past year, evidenced by a 1-year price change of +18.78%, but is currently experiencing a significant pullback from recent highs. As of the latest close at $336.79, the price sits at approximately 56% of its 52-week range ($267.83 to $391.29), indicating a retreat from peak levels and positioning it in the lower half of its annual band, which may signal a value opportunity if fundamentals hold but also reflects recent negative momentum. Recent momentum has sharply diverged from the longer-term uptrend, with the stock down 13.23% over the past 3 months and 0.36% over the past month, suggesting a pronounced deceleration and potential consolidation or correction phase; this is further underscored by a relative strength of -23.51 against the SPY over 3 months, highlighting significant underperformance. Key technical support is at the 52-week low of $267.83, while resistance is at the 52-week high of $391.29; a sustained break below the recent trading range could signal a deeper correction, whereas reclaiming the $370-$380 area would suggest trend resumption. The stock's beta of 0.435 indicates it is significantly less volatile than the broader market, which typically implies lower risk but also muted responsiveness to market rallies, a factor important for risk-adjusted portfolio construction.
Beta
0.43
0.43x market volatility
Max Drawdown
-16.6%
Largest decline past year
52-Week Range
$268-$391
Price range past year
Annual Return
+13.8%
Cumulative gain past year
| Period | AMGN Return | S&P 500 |
|---|---|---|
| 1m | -0.5% | +5.4% |
| 3m | -13.4% | +10.9% |
| 6m | -3.5% | +11.0% |
| 1y | +13.8% | +28.1% |
| ytd | +0.2% | +11.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
AMGN Fundamental Analysis
Revenue growth is positive but shows variability, with Q4 2025 revenue of $9.896 billion representing a solid 8.91% year-over-year increase; however, examining sequential quarters reveals volatility, from $9.557 billion in Q3 to $9.167 billion in Q2 and $8.149 billion in Q1, indicating lumpy performance likely influenced by product timing and the Horizon integration. The company is profitable with a net income of $1.333 billion in Q4 2025, supported by a robust gross margin of 81.91% for that quarter, which is exceptionally high for the industry; profitability margins have fluctuated significantly across recent quarters (net income ratios of 13.47% in Q4, 33.65% in Q3, 15.62% in Q2), reflecting one-time items and integration costs impacting consistency. Financial health is characterized by a strong cash position with free cash flow (TTM) of $8.1 billion, but this is offset by a very high debt-to-equity ratio of 6.31, indicating aggressive leverage used for acquisitions; the current ratio of 1.14 suggests adequate short-term liquidity, while the return on equity of 89.06% is inflated by the high financial leverage, pointing to a balance sheet carrying significant debt burden post-Horizon deal.
Quarterly Revenue
$9.9B
2025-12
Revenue YoY Growth
+0.08%
YoY Comparison
Gross Margin
+0.81%
Latest Quarter
Free Cash Flow
$8.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is AMGN Overvalued?
Given a positive net income, the primary valuation metric is the P/E ratio. The trailing P/E is 22.84x, while the forward P/E is notably lower at 14.35x, implying the market expects a significant earnings increase, likely from the full integration of the Horizon acquisition and cost synergies. Compared to sector averages, Amgen's trailing P/E of 22.84x and Price/Sales of 4.79x are not directly comparable without provided industry benchmarks, but the forward P/E discount to the trailing multiple suggests the market is pricing in improved profitability. Historically, the current trailing P/E of 22.84x sits below the recent quarterly highs seen in 2024 (e.g., 56.17x in Q4 2024) and is towards the middle of its own range over the past few years, indicating the stock is not at extreme historical valuation levels and may reflect a more balanced expectation of future earnings growth post-acquisition volatility.
PE
22.8x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -336x~75x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
14.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are primarily centered on Amgen's leveraged capital structure. The debt-to-equity ratio of 6.31 is alarmingly high and was incurred to fund the Horizon acquisition. While strong free cash flow of $8.1 billion TMT provides a service cushion, quarterly profitability has been volatile, with net income margin swinging from 33.65% in Q3 2025 to 13.47% in Q4 2025 due to integration costs and other items. This earnings inconsistency, coupled with $653 million in quarterly interest expense, creates vulnerability to any slowdown in cash generation or rise in interest rates, pressuring the balance sheet.
Market & Competitive Risks include valuation compression for a stock trading at a forward P/E of 14.35x if earnings growth fails to materialize as expected. External threats are pronounced, including severe regulatory scrutiny over Tavneos (fatal liver risk warnings) and the evolving U.S. drug tariff landscape, which could disadvantage companies without pricing deals. Furthermore, Amgen's low beta of 0.435, while defensive, also implies it may not fully participate in market rallies, as evidenced by its significant underperformance (-23.51 relative strength) over the past three months during a rising market.
Worst-Case Scenario involves a combination of a major Tavneos safety setback leading to commercial restrictions or withdrawal, coupled with a failure to realize Horizon acquisition synergies. This could trigger earnings misses, leading to a credit rating review, increased cost of capital, and a rapid de-rating of the stock multiple. The realistic downside could see the stock re-test its 52-week low of $267.83, representing a potential loss of approximately -20% from the current price of $336.79. A more severe scenario incorporating a sector-wide multiple compression could drive the price toward the analyst low EPS estimate implied valuation, deepening the loss further.
FAQ
The key risks are, in order of severity: 1) Financial Risk: Extremely high debt-to-equity (6.31) which increases vulnerability to interest rate rises and limits flexibility. 2) Regulatory/Commercial Risk: Severe safety warnings and scrutiny for Tavneos, a key Horizon asset, which could impact sales and trigger further regulatory action. 3) Execution Risk: Volatile quarterly earnings (net income margin swing from 33.7% to 13.5%) indicating challenges in smoothly integrating the Horizon acquisition and delivering consistent profits. 4) Macro/Policy Risk: Exposure to changes in U.S. drug pricing policy and potential tariffs, creating cost and competitive uncertainty.
The 12-month forecast presents three scenarios. The base case (55% probability) sees the stock trading between $350 and $380, driven by earnings meeting the analyst consensus of ~$27.52 EPS. The bull case (30% probability) could see a run toward $391-$420 if Horizon synergies exceed plans and Tavneos concerns fade. The bear case (15% probability) risks a decline to $268-$320 if integration stumbles or regulatory issues worsen. The most likely outcome is the base case, predicated on the assumption that management executes adequately on its stated integration plan without major setbacks.
Based on forward earnings, AMGN appears fairly valued to slightly undervalued. The trailing P/E of 22.84x is not extreme for a profitable biotech, but the forward P/E of 14.35x suggests the market is pricing in a substantial earnings increase. This implies the stock is not overvalued if those earnings materialize. Compared to its own historical P/E (which has been as high as 56x), it is at a more reasonable level. The valuation implies the market expects successful Horizon integration and EPS growth to ~$27.52, a bet that is currently priced in but not at a premium.
AMGN is a conditional buy for patient, risk-aware investors. The forward P/E of 14.35x offers value if the company delivers on expected earnings growth from the Horizon acquisition. However, it carries significant risks, including a very high debt load (D/E of 6.31) and regulatory concerns over key drug Tavneos. For investors seeking a defensive healthcare holding with income, it could be a good buy on further weakness (e.g., below $320). For growth-oriented investors or those uncomfortable with balance sheet leverage, it is less attractive.
AMGN is more suitable for a long-term investment horizon (minimum 2-3 years). Its low beta (0.435) and dividend make it a poor candidate for short-term trading, as it typically exhibits lower volatility and muted responses to market moves. The investment thesis hinges on the multi-year integration of the Horizon acquisition and the long-term commercial performance of its pipeline. Short-term price action is likely to be noisy due to quarterly earnings volatility and regulatory news flow. Long-term investors can benefit from the cash flow generation and potential valuation re-rating as debt is paid down and earnings stabilize.